A new tablet, orforglipron, helped people with type 2 diabetes lose up to 8% of body weight.
The drug works on GLP-1 receptors, lowers blood sugar, and reduces appetite.
Patients can take it without fasting.
In a year-long phase 3 trial, it outperformed oral semaglutide for weight loss and glucose control.
More participants stopped treatment because of stomach side effects.
Regulators have not yet approved the pill.
Experts see oral therapies as easier, cheaper, and widely accessible.
They expect these drugs to become key treatments for diabetes and obesity.
